lifestyle.thenyctimes.com

Author: Spyre Therapeutics, Inc.

Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock

April 14, 2026
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

April 13, 2026
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

April 13, 2026
Spyre Therapeutics Announces Grants of Inducement Awards

April 3, 2026
Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026

March 16, 2026
Spyre Therapeutics Announces Grants of Inducement Awards

March 6, 2026
Spyre Therapeutics to Participate in Upcoming March Investor Conferences

February 24, 2026
Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

February 19, 2026
Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach

February 18, 2026
Spyre Therapeutics Announces Grants of Inducement Awards

February 11, 2026